MedPath

Effect of dexmedetomidine with bupivacaine in turp

Completed
Conditions
Medical and Surgical,
Registration Number
CTRI/2019/02/017789
Lead Sponsor
Department of anaesthesiology Jln Medical College ajmer
Brief Summary

To study the effects of intrathecal dexmedetomidine as an adjuvant to low dose bupivacaine in patients undergoing transurethral resection of prostate with respect to: PRIMARY OBJECTIVE: 1. Duration of analgesia SECONDARY OBJECTIVES: 1. Block characteristics (onset and duration of sensory and motor block ). 2. First rescue analgesic requirement. 3. Total rescue analgesic requirement in 24 hour. 4. Haemodynamic changes. 5. Side effects, if any.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
100
Inclusion Criteria
  • 1.Male patients between 50 to 70 years of age.
  • 2.ASA physical status 1,2 and 3.
Exclusion Criteria
  • ASA physical status 4,5 & 6.
  • Patients refusal.3. Patients with peripheral sensorineural deficit.
  • Patients is sensitive or allergic to study medications.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Duration of analgesiaDuration of study is around 1 year
Secondary Outcome Measures
NameTimeMethod
1. ASA physical status 4,5 and 6. 2. Patients refusal. 3. Patients with peripheral sensorineural deficit. 4. Patients is sensitive or allergic to study medications. 5. Patients on anticoagulants. 6. Infection at the site of of lumbar puncture. 7. Patients who are taking α2 adrenergic agonist or antagonists. 8. Pre existing severe cardiac disease, heart block/dysrhythmias. 9. Contraindications to subarachnoid block.Duration of study is around one year

Trial Locations

Locations (1)

Jln Medical College ajmer

🇮🇳

Ajmer, RAJASTHAN, India

Jln Medical College ajmer
🇮🇳Ajmer, RAJASTHAN, India
Dr Aakriti Sharma
Principal investigator
07014321360
aakritias2017@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.